Low-dose Buprenorphine Initiation in Pregnancy: A Systematic ReviewLow-dose Buprenorphine Initiation in Pregnancy: A Systematic Review
Addiction Medicine: Beyond the Abstract
Dr Kathleen Adams discusses her systematic review on low-dose buprenorphine initiation in pregnancy, outlining practical protocol design, reported outcomes and key research gaps. The conversation also touches on humane care for opioid use disorder and candid advice on building a research career in this area.
24:10•18 Jun 2026
Low‑Dose Buprenorphine in Pregnancy: A Kinder Path Through Opioid Treatment?
Episode Overview
- Low-dose buprenorphine initiation can help pregnant patients transition without requiring full opioid withdrawal, with high transition rates and low rates of severe withdrawal reported in small cohorts.
- Operational details such as dosage form, cost, and hospital rules around manipulating medicines are crucial for making any protocol usable in real clinical settings.
- Current evidence on low-dose initiation is largely based on case reports and case series, and inconsistent reporting and definitions limit the strength of conclusions.
- Validated tools like COWS and SOWS, along with clear definitions of withdrawal and successful transition, are essential to make studies comparable and clinically useful.
- For early-career clinicians and researchers, rejection from journals does not always mean the work lacks value; finding the right audience and engaging critically with feedback are key.
“We really normalised a level of suffering for those with opioid use disorder that we would consider unacceptable with other chronic diseases.”
How do different strategies aid in addiction recovery? This episode turns that question toward pregnant patients with opioid use disorder and the use of low-dose buprenorphine initiation. Journal Podcast Editor Shawn McNeil, MD chats with Dr Kathleen Adams, an associate clinical professor at the University of Connecticut School of Pharmacy and Pharmaceutical Sciences.
She talks through her systematic review on low-dose buprenorphine initiation in pregnancy, sharing how a very practical problem in her hospital sparked a line of research that has grown from single case reports to hundreds of documented cases. You’ll hear how Adams, a general medicine pharmacist, was drawn into addiction medicine “kind of by accident” to meet an unmet clinical need in the Yale New Haven Health System.
She explains why her team moved away from expensive patches and awkwardly quartered films and instead adapted an existing protocol to a buccal formulation, belbuca, to avoid manipulating dosage forms and to keep costs realistic. A big focus is the potential benefit for pregnant patients: transitioning to buprenorphine without forcing them through full withdrawal.
Adams notes that in both pregnancy-specific data and a larger general cohort, about 80% of patients made a successful transition, severe or precipitated withdrawal was uncommon, and nothing in the maternal or neonatal outcomes suggested that this approach could not be used. She also highlights why standard definitions and validated tools like COWS and SOWS matter so much for interpreting case reports, and how inconsistent reporting limits what clinicians can safely conclude.
On a more personal note, Adams shares candid advice for early-career clinicians and researchers facing rejection, stressing that, “a rejection doesn’t necessarily mean that you’re wrong.” If you’re interested in evidence-based yet humane options for opioid use disorder in pregnancy, this conversation offers clear data, honest caveats, and plenty to think about. Could low-dose buprenorphine become a kinder standard for patients who are already carrying so much?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.